220 related articles for article (PubMed ID: 37858338)
1. High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma.
Arang N; Lubrano S; Ceribelli M; Rigiracciolo DC; Saddawi-Konefka R; Faraji F; Ramirez SI; Kim D; Tosto FA; Stevenson E; Zhou Y; Wang Z; Bogomolovas J; Molinolo AA; Swaney DL; Krogan NJ; Yang J; Coma S; Pachter JA; Aplin AE; Alessi DR; Thomas CJ; Gutkind JS
Cell Rep Med; 2023 Nov; 4(11):101244. PubMed ID: 37858338
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Darovasertib (NVP-LXS196), a Pan-PKC Inhibitor for the Treatment of Metastatic Uveal Melanoma.
Visser M; Papillon JPN; Luzzio M; LaMarche MJ; Fan J; Michael W; Wang D; Zhang A; Straub C; Mathieu S; Kato M; Palermo M; Chen C; Ramsey T; Joud C; Barrett R; Vattay A; Guo R; Bric A; Chung F; Liang G; Romanowski MJ; Lam J; Thohan S; Atassi F; Wylie A; Cooke VG
J Med Chem; 2024 Jan; 67(2):1447-1459. PubMed ID: 38198520
[TBL] [Abstract][Full Text] [Related]
3. Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling.
Park JJ; Stewart A; Irvine M; Pedersen B; Ming Z; Carlino MS; Diefenbach RJ; Rizos H
Cancer Gene Ther; 2022 Oct; 29(10):1384-1393. PubMed ID: 35352024
[TBL] [Abstract][Full Text] [Related]
4. Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for
Paradis JS; Acosta M; Saddawi-Konefka R; Kishore A; Gomes F; Arang N; Tiago M; Coma S; Lubrano S; Wu X; Ford K; Day CP; Merlino G; Mali P; Pachter JA; Sato T; Aplin AE; Gutkind JS
Clin Cancer Res; 2021 Jun; 27(11):3190-3200. PubMed ID: 33568347
[TBL] [Abstract][Full Text] [Related]
5. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.
Chen X; Wu Q; Tan L; Porter D; Jager MJ; Emery C; Bastian BC
Oncogene; 2014 Sep; 33(39):4724-34. PubMed ID: 24141786
[TBL] [Abstract][Full Text] [Related]
6. RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma.
Chen X; Wu Q; Depeille P; Chen P; Thornton S; Kalirai H; Coupland SE; Roose JP; Bastian BC
Cancer Cell; 2017 May; 31(5):685-696.e6. PubMed ID: 28486107
[TBL] [Abstract][Full Text] [Related]
7. Copper ionophore elesclomol selectively targets GNAQ/11-mutant uveal melanoma.
Li Y; Yang J; Zhang Q; Xu S; Sun W; Ge S; Xu X; Jager MJ; Jia R; Zhang J; Fan X
Oncogene; 2022 Jul; 41(27):3539-3553. PubMed ID: 35697803
[TBL] [Abstract][Full Text] [Related]
8. The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells.
Musi E; Ambrosini G; de Stanchina E; Schwartz GK
Mol Cancer Ther; 2014 May; 13(5):1044-53. PubMed ID: 24563540
[TBL] [Abstract][Full Text] [Related]
9. Protein kinase C inhibitors sensitize GNAQ mutant uveal melanoma cells to ionizing radiation.
Cerne JZ; Hartig SM; Hamilton MP; Chew SA; Mitsiades N; Poulaki V; McGuire SE
Invest Ophthalmol Vis Sci; 2014 Apr; 55(4):2130-9. PubMed ID: 24595385
[TBL] [Abstract][Full Text] [Related]
10. The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.
Wu X; Zhu M; Fletcher JA; Giobbie-Hurder A; Hodi FS
PLoS One; 2012; 7(1):e29622. PubMed ID: 22253748
[TBL] [Abstract][Full Text] [Related]
11. A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK.
Feng X; Arang N; Rigiracciolo DC; Lee JS; Yeerna H; Wang Z; Lubrano S; Kishore A; Pachter JA; König GM; Maggiolini M; Kostenis E; Schlaepfer DD; Tamayo P; Chen Q; Ruppin E; Gutkind JS
Cancer Cell; 2019 Mar; 35(3):457-472.e5. PubMed ID: 30773340
[TBL] [Abstract][Full Text] [Related]
12. Combined PKC and MEK inhibition for treating metastatic uveal melanoma.
Sagoo MS; Harbour JW; Stebbing J; Bowcock AM
Oncogene; 2014 Sep; 33(39):4722-3. PubMed ID: 24413085
[TBL] [Abstract][Full Text] [Related]
13. Chloroquine Sensitizes
Truong A; Yoo JH; Scherzer MT; Sanchez JMS; Dale KJ; Kinsey CG; Richards JR; Shin D; Ghazi PC; Onken MD; Blumer KJ; Odelberg SJ; McMahon M
Clin Cancer Res; 2020 Dec; 26(23):6374-6386. PubMed ID: 32933997
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of chromosomal aberrations and GNAQ, GNA11 and BAP1 mutations in uveal melanoma.
Staby KM; Gravdal K; Mørk SJ; Heegaard S; Vintermyr OK; Krohn J
Acta Ophthalmol; 2018 Feb; 96(1):31-38. PubMed ID: 28444874
[TBL] [Abstract][Full Text] [Related]
15. BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells.
Ambrosini G; Sawle AD; Musi E; Schwartz GK
Oncotarget; 2015 Oct; 6(32):33397-409. PubMed ID: 26397223
[TBL] [Abstract][Full Text] [Related]
16. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.
Khalili JS; Yu X; Wang J; Hayes BC; Davies MA; Lizee G; Esmaeli B; Woodman SE
Clin Cancer Res; 2012 Aug; 18(16):4345-55. PubMed ID: 22733540
[TBL] [Abstract][Full Text] [Related]
17. Combined Mcl-1 and YAP1/TAZ inhibition for treatment of metastatic uveal melanoma.
Glinkina KA; Teunisse AFAS; Gelmi MC; de Vries J; Jager MJ; Jochemsen AG
Melanoma Res; 2023 Oct; 33(5):345-356. PubMed ID: 37467061
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity in Mitogen-Activated Protein Kinase (MAPK) Pathway Activation in Uveal Melanoma With Somatic GNAQ and GNA11 Mutations.
Boru G; Cebulla CM; Sample KM; Massengill JB; Davidorf FH; Abdel-Rahman MH
Invest Ophthalmol Vis Sci; 2019 Jun; 60(7):2474-2480. PubMed ID: 31173078
[TBL] [Abstract][Full Text] [Related]
19. Whole-genome CRISPR screening identifies PI3K/AKT as a downstream component of the oncogenic GNAQ-focal adhesion kinase signaling circuitry.
Arang N; Lubrano S; Rigiracciolo DC; Nachmanson D; Lippman SM; Mali P; Harismendy O; Gutkind JS
J Biol Chem; 2023 Feb; 299(2):102866. PubMed ID: 36596361
[TBL] [Abstract][Full Text] [Related]
20. Targeting GNAQ/11 through PKC inhibition in uveal melanoma.
Lietman CD; McKean M
Cancer Gene Ther; 2022 Dec; 29(12):1809-1813. PubMed ID: 35181742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
